A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Inclusion Criteria: * Diagnosis of Enthesitis Related Arthritis (ERA) as defined by International League of Associations for Rheumatology (ILAR); * Disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location; * Inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate. Exclusion Criteria: * Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA; * Psoriasis or a history of psoriasis in the patient or first-degree relative; * Presence of Immunoglobulin M (IgM) rheumatoid factor; * Presence of systemic JIA; * History of inflammatory bowel disease; * previous biologic therapy including anti-tumor necrosis factor (anti-TNF) therapy with a potential impact on pediatric ERA; * Infection(s) requiring treatment with IV anti-infectives within 30 days prior to Baseline or oral anti-infectives within 14 days prior to Baseline.